Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices

化学 基于生理学的药代动力学模型 药代动力学 生物利用度 药理学 溶解试验 色谱法 溶解 体内 生物制药分类系统 有机化学 医学 生物 生物技术
作者
Xavier Pépin,Andrea Moir,James Mann,Natalie Sanderson,Richard A. Barker,E. J. Meehan,A. Philip Plumb,George R. Bailey,Dean S. Murphy,Cecile M. Krejsa,Marilee Andrew,Timothy G. Ingallinera,J. Greg Slatter
出处
期刊:European Journal of Pharmaceutics and Biopharmaceutics [Elsevier BV]
卷期号:142: 435-448 被引量:40
标识
DOI:10.1016/j.ejpb.2019.07.011
摘要

Acalabrutinib (Calquence®) 100 mg (bid) has received accelerated approval by FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a substrate of PgP and CYP3A4, with a significant fraction of drug metabolized by first pass gut extraction and 25% absolute bioavailability. The absorption of acalabrutinib is affected by stomach pH, with lower pharmacokinetic exposure observed following co-administration with proton pump inhibitors. During dissolution at pH values below its highest basic pKa, the two basic moieties of acalabrutinib react with protons from the aqueous solution, leading to a higher pH at the drug surface than in the bulk solution. A batch-specific product particle size distribution (P-PSD), was derived from dissolution data using a mechanistic model that was based on the understanding of surface pH and the contribution of micelles to the dissolution rate. P-PSD values obtained for various batches of acalabrutinib products in simple buffers, or in complex fluids such as fruit juices, were successfully integrated into a physiologically based pharmacokinetic (PBPK) model developed using GastroPlus v9.0™. The integrated model allowed the prediction of clinical pharmacokinetics under normal physiological stomach pH conditions as well as following treatment with proton pump inhibitors. The model also accounted for lower pharmacokinetic exposure that was observed when acalabrutinib was co-administered with the acidic beverages, grapefruit juice, (which contains CYP3A inhibitors), and orange drink (which does not contain CYP3A inhibitors), relative to administration with water. The integration of dissolution data in the PBPK model enables mechanistic understanding and the establishment of more robust in vitro-in vivo correlations (IVIVC) under a variety of conditions. The model can then distinguish the interplay between dissolution and first pass extraction and how in vivo stomach pH, saturation of gut PgP, and saturation or inhibition of gut CYP3A4, will impact the pharmacokinetics of acalabrutinib.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ffffwj2024完成签到,获得积分10
刚刚
阿拉丁的应助被zoey采纳,获得10
刚刚
fu发布了新的文献求助10
刚刚
LiWanyi发布了新的文献求助10
刚刚
情怀的应助被Fun_112采纳,获得10
1秒前
1秒前
风趣的藏今完成签到,获得积分10
1秒前
1秒前
JUDY发布了新的文献求助10
2秒前
成就小蜜蜂完成签到,获得积分20
3秒前
科目三的应助被素素素采纳,获得10
3秒前
3秒前
4秒前
4秒前
jsj完成签到,获得积分10
4秒前
太兰完成签到 ,获得积分10
5秒前
5秒前
CodeCraft的应助被莹亮的星空采纳,获得10
6秒前
深情安青的应助被LiWanyi采纳,获得10
6秒前
7秒前
cherry发布了新的文献求助10
8秒前
卷石鱼完成签到 ,获得积分10
8秒前
小高子发布了新的文献求助10
8秒前
8秒前
Somehow完成签到,获得积分10
8秒前
叶伟帮完成签到,获得积分10
9秒前
9秒前
9秒前
小炮弹发布了新的文献求助10
10秒前
科研通AI65的应助被jenny采纳,获得10
10秒前
vv发布了新的文献求助10
10秒前
林间听鸟语完成签到,获得积分10
11秒前
yuyan发布了新的文献求助30
11秒前
11秒前
balabala完成签到,获得积分10
12秒前
ommmw发布了新的文献求助30
12秒前
13秒前
13秒前
joshar完成签到,获得积分10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175429
求助须知:如何正确求助?哪些是违规求助? 9567162
关于积分的说明 21790896
捐赠科研通 7769976
什么是DOI,文献DOI怎么找? 3431849
关于科研通互助平台的介绍 2556237
邀请新用户注册赠送积分活动 2477281